TOP TEN perturbations for 1553176_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553176_at
Selected probe(set): 1553177_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553176_at (1553177_at) across 6672 perturbations tested by GENEVESTIGATOR:

rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)

Relative Expression (log2-ratio):4.3386703
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (mono; CD14+ CD16+)
Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm
Control rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-4.2700806
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-3.9069405
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):3.8148794
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM-like)
Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

MALT lymphoma study 1 / normal spleen tissue

Relative Expression (log2-ratio):-3.6898823
Number of Samples:8 / 6
Experimental MALT lymphoma study 1
Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

inclusion body myositis study 1 / dermatomyositis study 3

Relative Expression (log2-ratio):-3.3009634
Number of Samples:5 / 5
Experimental inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control dermatomyositis study 3
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of dermatomyositis (DM).

MALT lymphoma study 2 / normal spleen tissue

Relative Expression (log2-ratio):-3.278244
Number of Samples:6 / 6
Experimental MALT lymphoma study 2
Human t(11;18)-positive mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

myotonic dystrophy study 4 (deltoid muscle; DM-like) / myotonic dystrophy study 4 (deltoid muscle; DM2)

Relative Expression (log2-ratio):3.148735
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM-like)
Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control myotonic dystrophy study 4 (deltoid muscle; DM2)
Deltoid muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2).

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-3.1231756
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

ALL study 2 (15d) / ALL study 2 (0d)

Relative Expression (log2-ratio):2.9367504
Number of Samples:45 / 129
Experimental ALL study 2 (15d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken 15 days after remission-induction therapy (RIT).
Control ALL study 2 (0d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).